It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Copper ions play various roles in mammalian cells, presumably due to their involvement in different enzymatic reactions. Some studies indicated that serum copper correlates with fibrosis in organs, such as liver and lung. However, the mechanism is unknown. Here, we explored the role of copper in kidney fibrosis development and possible underlying mechanisms. We found that copper transporter 1 (CTR1) expression was increased in the kidney tissues in two fibrosis models and in patients with kidney fibrosis. Similar results were also found in renal tubular epithelial cells and fibroblast cells treated with transforming growth factor beta (TGF-β). Mechanistically, the upregulation of CTR1 required Smads-dependent TGF-β signaling pathway and Smad3 directly binded to the promoter of CTR1 in renal fibroblast cells using chromatin immunoprecipitation. Elevated CTR1 induced increase of copper intracellular influx. The elevated intracellular copper ions activated lysyl oxidase (LOX) to enhance the crosslinking of collagen and elastin, which then promoted kidney fibrosis. Reducing intracellular copper accumulation by knocking down CTR1 ameliorated kidney fibrosis in unilateral ureteral obstruction induced renal fibrosis model and renal fibroblast cells stimulated by TGF-β. Treatment with copper chelator tetrathiomolybdate (TM) also alleviated renal fibrosis in vivo and in vitro. In conclusion, intracellular copper accumulation plays a unique role to kidney fibrosis by activating LOX mediated collagen and elastin crosslinking. Inhibition of intracellular copper overload may be a potential portal to alleviate kidney fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Tongji University School of Medicine, Department of Nephrology, Shanghai Tongji Hospital, Shanghai, China (GRID:grid.24516.34) (ISNI:0000000123704535)
2 University of Shanghai for Science and Technology, Terahertz Technology Innovatio, Research Institute, Shanghai Key Lab of Modern Optical System, Terahertz, Science Cooperative Innovation Center, School of Optical-Electrical Computer, Engineering, Shanghai, China (GRID:grid.267139.8) (ISNI:0000 0000 9188 055X)
3 Shanghai University of Medicine & Health Sciences, Department of Ultrasound, Zhoupu Hospital, Shanghai, China (GRID:grid.39436.3b) (ISNI:0000 0001 2323 5732)
4 EnnovaBio Pharmaceuticals Co., Ltd, Shanghai, China (GRID:grid.39436.3b)
5 Intervention and Technology, Karolinska Institutet, Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)